De-Identified Health Data Market Outlook: Strong Revenue and CAGR Growth Forecast Through 2029

 Use Code ONLINE20 to Save 20% On Global Market Reports — Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics

 

 What Is the Forecasted Market Size of the De-Identified Health Data Market by 2029?
 The de-identified health data market size has grown rapidly in recent years. It will grow from $8.20 billion in 2024 to $9.20 billion in 2025 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to growing adoption of electronic health records, rising awareness of patient data privacy, a surge in healthcare analytics usage, increasing research on population health management, expansion of health information technology systems, and growing use of data in clinical trials.
 
 The de-identified health data market size is expected to see rapid growth in the next few years. It will grow to $14.40 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to expanding use of artificial intelligence in healthcare, rising demand for real-world evidence in drug development, rising focus on secondary use of health data, a surge in demand for privacy-enhancing technology, and growing demand for precision medicine. Major trends in the forecast period include developing data privacy protocols, developing machine learning pipelines, integrating with electronic health records, integrating with population health platforms, and innovation in data anonymization techniques.
 
 Get your free report sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=28191&type=smp
 
 What Are the Significant Market Forces Driving the De-Identified Health Data Market Performance?
 The increasing adoption of electronic health records (EHRs) is expected to propel the growth of the de-identified health data market going forward. Electronic health records (EHR) refer to a digital version of a patient’s comprehensive medical history, including diagnoses, treatments, medications, lab results, and other health information securely stored and shared across authorized healthcare providers. The adoption of electronic health records is increasing due to their ability to enhance patient care and safety through accurate, real-time access to comprehensive medical information. De-identified health data enhances electronic health records by enabling secure data sharing and advanced analytics while protecting patient privacy, ultimately improving clinical decision-making and healthcare outcomes. For instance, in June 2022, according to the Department of Health and Social Care, a UK-based government department, it is anticipated that by March 2025, all NHS trusts will have implemented electronic health records, an increase from the 90% adoption rate recorded in December 2023. Therefore, the rising adoption of electronic health records (EHRs) is driving the growth of the de-identified health data market.
 
 What Are the Primary Market Segments in the De-Identified Health Data Market?
 The de-identified health data market covered in this report is segmented as
 
 1) By Type: Clinical Data, Genomic Data, Patient Demographics, Prescription Data, Hospital And Provider Data, Pharmacogenomic Data
 2) By Application: Clinical Research And Trials, Public Health, Precision Medicine, Health Economics And Outcomes Research (HEOR), Population Health Management, Drug Discovery And Development, Healthcare Quality Improvement, Insurance Underwriting And Risk Assessment, Other Applications 
 3) By End-User: Pharmaceutical Companies, Biotechnology Firms, Healthcare Providers, Insurance Companies Or Healthcare Payers, Research Institutions, Government Agencies, Other End-Users
 
 Subsegments:
 1) By Clinical Data: Electronic Health Records, Medical Imaging Data, Laboratory Test Results, Surgical Reports, Pathology Reports, Vital Signs Measurements
 2) By Genomic Data: Whole Genome Sequencing Data, Exome Sequencing Data, Single Nucleotide Polymorphism Data, Gene Expression Profiles, Epigenetic Data
 3) By Patient Demographics: Age Information, Gender Information, Ethnicity Information, Geographic Location, Socioeconomic Status, Marital Status
 4) By Prescription Data: Medication Orders, Dosage Information, Prescription Refill History, Drug Allergies, Pharmacy Dispensation Records
 5) By Hospital And Provider Data: Provider Performance Metrics, Care Delivery Outcomes, Billing And Claims Data, Resource Utilization Data
 6) By Pharmacogenomic Data: Gene–Drug Interaction Data, Adverse Drug Reaction Data, Personalized Therapy Response Data, Drug Efficacy Variation Data
 
 What New Market Trends Are Emerging in the De-Identified Health Data Market?
 Major companies operating in the de-identified health data market are focusing on developing advanced solutions, such as real-world biomarker coverage applications, to support evidence-based healthcare decision-making. A real-world biomarker coverage application leverages de-identified patient data to monitor and assess biomarker patterns and effectiveness across diverse populations outside clinical trials, enabling researchers and healthcare providers to gain insights into treatment responses and disease trends. For instance, in July 2025, Datma Inc., a US-based healthcare technology company, launches the Federated Biomarker Explorer, a free application designed for pharmaceutical teams to quickly validate real-world biomarker coverage across Datma’s federated network of participating data contributors. The tool provides aggregate, cohort-level insights into biomarker presence, enabling teams to assess coverage quickly without the need for contracts or IT support. It also allows secure integration of users’ own data for overlap analysis and facilitates early-stage feasibility assessments with clinical and demographic filtering, helping validate whether datasets include the necessary patient populations before committing resources.
 
 Who Are the Established and Emerging Companies Competing in the De-Identified Health Data Market?
 Major companies operating in the de-identified health data market are UnitedHealth Group Incorporated, Oracle Corporation, IQVIA Holdings Inc, ICON Public Limited Company, Datavant Inc, Premier Inc., iMerit Technology Services Pvt. Ltd., Tempus Labs Inc., Medidata Solutions Inc., Veradigm Inc., Flatiron Health, Merative LP, Komodo Health Inc., Shaip Inc., Truveta Inc., Evidation Health Inc., TriNetX Inc., Clarify Health Solutions Inc., Akrivia Health Ltd., Gradient Health Inc.
 
 Get the detailed de-identified health data market report today
 https://www.thebusinessresearchcompany.com/report/de-identified-health-data-global-market-report
 
 Which Region Is Expected to Dominate the De-Identified Health Data Market During the Forecast Period?
 North America was the largest region in the de-identified health data market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in de-identified health data report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company